Vanguard Capital Management filed an amended beneficial ownership statement with the SEC on October 30, 2026, disclosing a position of 8,187,183 shares of common stock in Cabaletta Bio Inc (NASDAQ:CABA) as of September 30, 2026.

Key Highlights

  • Total beneficial ownership: Vanguard Capital Management reported aggregate beneficial ownership of 8,187,183 shares of Cabaletta Bio common stock.
  • Percent of class: The reported position represents 3.79% of Cabaletta Bio's outstanding common stock.
  • Sole voting power: Vanguard Capital Management holds sole voting power over 1,042,425 shares, with 0 shares subject to shared voting power.
  • Sole dispositive power: Sole power to dispose of all 8,187,183 shares is attributed to Vanguard Capital Management, with no shared dispositive power reported.
  • Triggering event date: The date of the event requiring this filing was September 30, 2026.
  • Filing type: This is Amendment No. 1 to the original statement, signed by My Trieu-Gatt, Authorized Signatory and Head of Global Fund Administration.

Vanguard's Amended Position in Cabaletta Bio as of September 30, 2026

According to the filing, Vanguard Capital Management, organized in Pennsylvania and headquartered at 100 Vanguard Blvd, Malvern, PA, submitted Amendment No. 1 disclosing its beneficial ownership stake in Cabaletta Bio Inc, a clinical-stage biopharmaceutical company headquartered at 2929 Arch Street, Suite 600, Philadelphia, PA, 19104. The filing identifies Vanguard Capital Management as an investment adviser (Type: IA) for the purposes of this disclosure. The common stock carries CUSIP number 12674W109.

The filing states that the position of 8,187,183 shares constitutes 3.79% of Cabaletta Bio's outstanding common stock class, falling below the 5% threshold. Vanguard Capital Management holds sole dispositive power over all 8,187,183 shares reported, while sole voting power extends to only 1,042,425 of those shares. No shared voting or shared dispositive power was reported. According to the filing, Vanguard Capital Management, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, holds the right to receive dividends or proceeds from sale of the reported securities, and no single other person's interest exceeds 5%.

The filing further notes, in accordance with SEC Release No. 34-39538 dated January 12, 1998, that the disclosure reflects securities beneficially owned or deemed to be beneficially owned by Vanguard Capital Management LLC and specified affiliates, including Vanguard Asset Management Limited, Vanguard Fiduciary Trust Company, Vanguard Global Advisers, LLC, and Vanguard Investments Australia Ltd. The filing certifies that the securities "were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer."

What Was Disclosed

Vanguard Capital Management filed an amended beneficial ownership statement covering 8,187,183 shares, or 3.79%, of Cabaletta Bio Inc common stock as of September 30, 2026, with sole dispositive power over the full position and sole voting power over 1,042,425 shares.